UPDATE: Credit Suisse Reiterates Outperform Rating, Raises PT on Esperion Therapeutics on Multiple Positive Factors

In a report published Thursday, Credit Suisse analyst Jason Kantor reiterated an Outperform rating on Esperion Therapeutics ESPR, and raised the price target from $26.00 to $38.00. In the report, Credit Suisse noted, “Study 008 clearly demonstrated the superior efficacy of ETC-1002 over Zetia and surprisingly strong data for the all oral combination ETC-1002 / Zetia. The safety profile was consistent with prior trials and more convincing with larger patient numbers, but long-term safety remains an open question. We are increasing our target to $38 from $26 with an increase to our probability of success to 60% from 55% in statin intolerant patients and to 45% from 33% in residual risk patients. Estimates increase on probability of success and forecast partnership.” Esperion Therapeutics closed on Wednesday at $24.42.